[11C]choline positron emission tomography in estrogen receptor-positive breast cancer

Clinical Cancer Research

Volumn 15, Issue 17, 2009, Pages 5503-5510

  Contractor, Kaiyumars B ^a   Kenny, Laura M ^a   Stebbing, Justin ^a   Al Nahhas, Adil ^b   Palmieri, Carlo ^a   Sinnett, Dudley ^c   Lewis, Jacqueline S ^c   Hogben, Katy ^c   Osman, Safiye ^b   Shousha, Sami ^c   Lowdell, Charles ^a   Coombes, R Charles ^a   Aboagye, Eric O ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE C 11; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; CARBON; CHOLINE; DIAGNOSTIC AGENT; ERBB2 PROTEIN, HUMAN; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CHOLINE UPTAKE; CLINICAL ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; IN VIVO STUDY; METASTASIS; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOACTIVITY; TUMOR VOLUME; BREAST TUMOR; METABOLISM; METHODOLOGY; PATHOLOGY; SCINTISCANNING;

BREAST NEOPLASMS; CARBON RADIOISOTOPES; CHOLINE; FEMALE; HUMANS; KI-67 ANTIGEN; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 69949091374     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0666     Document Type: Article

References (46)

1. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-1092 (Pubitemid 38298988)
2. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-1810
3. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002;2:101-112 (Pubitemid 37328797)
4. Thomas RS, Sarwar N, Phoenix F, Coombes RC, Ali S. Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-α activity. J Mol Endocrinol 2008;40:173-184 (Pubitemid 351586826)
5. Adeyinka A, Nui Y, Cherlet T, et al. Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res 2002;8:1747-1753 (Pubitemid 34633730)
6. Santen RJ, Song RX, Zhang Z, et al. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr Relat Cancer 2005;12 Suppl 1:S61-73. (Pubitemid 41395414)
7. Sarwar N, Kim JS, Jiang J, et al. Phosphorylation of ERα at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERα phosphorylation in breast cancer progression. Endocr Relat Cancer 2006;13:851-861 (Pubitemid 44763261)
8. Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-1494
9. Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996;15:2174-2183 (Pubitemid 26141134)
10. Sivaraman VS, Wang H, Nuovo GJ, Malbon CC. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 1997;99:1478-1483 (Pubitemid 27163797)
11. Gee JM, Robertson JF, Ellis IO. Nicholson RI Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 2001;95:247-254
12. Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005;11:2785-2808 (Pubitemid 40525178)
13. Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics 2007;27 Suppl 1:S215-29.
14. Kenny LM, Vigushin DM, Al-Nahhas A, et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res 2005;65:10104-10112 (Pubitemid 41541493)
15. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998;4:1334-1336
16. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998;39:990-995 (Pubitemid 28270113)
17. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999;59:80-84
18. Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 2004;64:4270-4276 (Pubitemid 38802433)
19. Ramirez de Molina A, Banez-Coronel M, Gutierrez R, et al. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res 2004;64:6732-6739 (Pubitemid 39297936)
20. Choi MG, Park TS, Carman GM. Phosphorylation of Saccharomyces cerevisiae CTPsynt hetase at Ser424 by protein kinases A and C regulates phosphatidylcholine synthesis by the CDP-choline pathway. J Biol Chem 2003;278:23610-23616
21. Liu D, Hutchinson OC, Osman S, et al. Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin. Br J Cancer 2002;87:783-789 (Pubitemid 35178757)
22. Ratnam S, Kent C. Early increase in choline kinase activity upon induction of the H-ras oncogene in mouse fibroblast cell lines. Arch Biochem Biophys 1995;323:313-322
23. Hernandez-Alcoceba R, Saniger L, Campos J, et al. Choline kinase inhibitors as a novel approach for antiproliferative drug design. Oncogene 1997;15:2289-2301 (Pubitemid 27496980)
24. Yu Y, Sreenivas A, Ostrander DB, Carman GM. Phosphorylation of Saccharomyces cerevisiae choline kinase on Ser30 and Ser85 by protein kinase A regulates phosphatidylcholine synthesis by the CDP-choline pathway. J Biol Chem 2002;277:34978-34986 (Pubitemid 35052392)
25. Ramirez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C, et al. Expression of choline kinase α to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol 2007;8:889-897 (Pubitemid 47488053)
26. Pascali CAB, Itawa R, Cambiè M, Bombardieri E. [11C]Methylation on a C18 Sep-Pak cartridge: a convenient way to produce [N-methyl-11C] choline. J Labelled Compds Radiopharm 2000;43:195-203.
27. 11C] choline, a positron-emitting tracer for tumor imaging. Appl Radiat Isot 1999;50:531-533
28. Lucignani G, Paganelli G, Bombardieri E. The use of standardized uptake values for assessing FDG uptake with PET in oncology: a clinical perspective. Nucl Med Commun 2004;25:651-656 (Pubitemid 38901681)
29. Hara T, Kosaka N, Shinoura N, Kondo T. PET imaging of brain tumor with [methyl-11C]choline. J Nucl Med 1997;38:842-847 (Pubitemid 27251970)
30. Mankoff DA, Shields AF, Graham MM, Link JM, Krohn KA. A graphical analysis method to estimate blood-to-tissue transfer constants for tracers with labeled metabolites. J Nucl Med 1996;37:2049-2057
31. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985;5:584-590
32. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer: I. The value of histologic grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-410
33. McCarty KS, Jr., Miller LS, Cox EB, Konrath J, McCarty KS, Sr. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985;109:716-721
34. Millis RR, Barnes DM, Lampejo OT, Egan MK, Smith P. Tumour grade does not change between primary and recurrent mammary carcinoma. Eur J Cancer 1998;34:548-553 (Pubitemid 28179353)
35. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 2007;9:R6.
36. D'Eredita G, Giardina C, Martellotta M, Natale T, Ferrarese F. Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution. Eur J Cancer 2001;37:591-596 (Pubitemid 32261016)
37. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 2002;296:580-583
38. Katz-Brull R, Margalit R, Bendel P, Degani H. Choline metabolism in breast cancer; 2H-, 13C- and 31P-NMR studies of cells and tumors. Magma 1998;6:44-52.
39. Ramirez de Molina A, Gallego-Ortega D, Sarmentero-Estrada J, et al. Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: implications in cancer therapy. Int J Biochem Cell Biol 2008;40:1753-1763
40. Hernandez-Alcoceba R, Fernandez F, Lacal JC. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Res 1999;59:3112-3118
41. Reske SN. [11C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging 2008;35:1740-1741
42. Reske SN, Blumstein NM, Glatting G. [11C] choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 2008;35:9-17.
43. Rinnab L, Simon J, Hautmann RE, et al. [(11)C] choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World J Urol 2009.
44. Al-Saffar NM, Troy H, Ramirez de Molina A, et al. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res 2006;66:427-434 (Pubitemid 43166051)
45. Conejo-Garcia A, Banez-Coronel M, Sanchez-Martin RM, et al. Influence of the linker in bispyridium compounds on the inhibition of human choline kinase. J Med Chem 2004;47:5433-5440 (Pubitemid 39386296)
46. Campos J, Nunez MC, Conejo-Garcia A, et al. QSAR-derived choline kinase inhibitors: how rational can antiproliferative drug design be? Curr Med Chem 2003;10:1095-1112